FDA’s Guidance Agenda Includes Risk Communication, Pain, Diabetes
Executive Summary
FDA is preparing to issue further guidance on appropriate communication of risk information over the next year, according to CDER's 2007 guidance agenda
You may also be interested in...
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
DTC Risk Disclosures Examined By FDA; Do Minor Risks Swamp Major Ones?
FDA will evaluate how the presence of minor safety risks in the brief summary of print direct-to-consumer advertisements impacts consumer comprehension of major risks